Downregulation of Sec23A protein by miRNA-375 in prostate carcinoma

Molecular Cancer Research

Volumn 9, Issue 6, 2011, Pages 791-800

  Szczyrba, Jaroslaw ^a   Nolte, Elke ^b,c   Wach, Sven ^b,c   Kremmer, Elisabeth ^d   Stöhr, Robert ^b   Hartmann, Arndt ^b   Wieland, Wolf ^e   Wullich, Bernd ^b   Grässer, Friedrich A ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

^e UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; MICRORNA; MICRORNA 375; MICRORNA200C; PROTEIN SEC23A; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BINDING SITE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; UPREGULATION;

APOPTOSIS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; MALE; MICRORNAS; PROSTATE; PROSTATIC NEOPLASMS; VESICULAR TRANSPORT PROTEINS;

EID: 79959188574     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-10-0573     Document Type: Article

References (39)

1. Coppola V, De Maria R, Bonci D. MicroRNAs and prostate cancer. Endocr Relat Cancer 2010;17:F1-17.
2. Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5′ UTR as in the 3′ UTR. Proc Natl Acad Sci USA 2007;104:9667-72. (Pubitemid 47175324)
3. Tay Y, Zhang J, Thomson AM, Lim B, Rigoutsos I. MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 2008;455:1124-8.
4. Meister G. miRNAs get an early start on translational silencing. Cell 2007;131:25-8.
5. Szczyrba J, Löprich E, Wach S, Jung V, Unteregger G, Barth S, et al. The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res 2010;8:529-38.
6. Barlowe C, Orci L, Yeung T, Hosobuchi M, Hamamoto S, Salama N, et al. COPII: a membrane coat formed by Sec proteins that drive vesicle budding from the endoplasmic reticulum. Cell 1994;77:895-907. (Pubitemid 24187687)
7. Paccaud JP, Reith W, Carpentier JL, Ravazzola M, Amherdt M, Schekman R, et al. Cloning and functional characterization of mammalian homologues of the COPII component Sec23. Mol Biol Cell 1996;7:1535-46. (Pubitemid 26339727)
8. Fromme JC, Ravazzola M, Hamamoto S, Al-Balwi M, Eyaid W, Boyadjiev SA, et al. The genetic basis of a craniofacial disease provides insight into COPII coat assembly. Dev Cell 2007;13:623-34. (Pubitemid 350011989)
9. Lang MR, Lapierre LA, Frotscher M, Goldenring JR, Knapik EW. Secretory COPII coat component Sec23a is essential for craniofacial chondrocyte maturation. Nat Genet 2006;38:1198-203. (Pubitemid 44470367)
10. Fromme JC, Orci L, Schekman R. Coordination of COPII vesicle trafficking by Sec23. Trends Cell Biol 2008;18:330-6.
11. Pfuhl T, Mamiani A, Dürr M, Welter S, Stieber J, Ankara J, et al. The LARK/RBM4a protein is highly expressed in cerebellum as compared to cerebrum. Neurosci Lett 2008;444:11-5.
12. Barth S, Pfuhl T, Mamiani A, Ehses C, Roemer K, Kremmer E, et al. Epstein-Barr virus-encoded microRNA miR-BART2 down-regulates the viral DNA polymerase BALF5. Nucleic Acids Res 2008;36:666-75.
13. Imig J, Motsch N, Zhu JY, Barth S, Okoniewski M, Reineke T, et al. microRNA profiling in Epstein-Barr virus-associated B-cell lymphoma. Nucleic Acids Res 2011;39:1880-93.
14. Wach S, Nolte E, Szczyrba J, Stöhr R, Hartmann A, Orntoft T, et al. MiRNA profiles of prostate carcinoma detected by multi-platform miRNA screening. Int J Cancer 2011 Mar 11. [Epub ahead of print].
15. Spizzo R, Nicoloso MS, Croce CM, Calin GA. SnapShot: microRNAs in cancer. Cell 2009;137:586.
16. Marchini S, Cavalieri D, Fruscio R, Calura E, Garavaglia D, Nerini IF, et al. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncol 2011;12:273-85.
17. Cochrane DR, Howe EN, Spoelstra NS, Richer JK. Loss of miR-200c: a marker of aggressiveness and chemoresistance in female reproductive cancers. J Oncol 2010;2010:821717.
18. Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti GV, Papotti M, et al. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res 2010;8:1207-16.
19. Mees ST, Mardin WA, Wendel C, Baeumer N, Willscher E, Senninger N, et al. EP300-a miRNA-regulated metastasis suppressor gene in ductal adenocarcinomas of the pancreas. Int J Cancer 2010;126:114-24.
20. Benjamin H, Lebanony D, Rosenwald S, Cohen L, Gibori H, Barabash N, et al. A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma. J Mol Diagn 2010;12:771-9.
21. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008;10:593-601. (Pubitemid 351627379)
22. Hurteau GJ, Carlson JA, Roos E, Brock GJ. Stable expression of miR-200c alone is sufficient to regulate TCF8 (ZEB1) and restore Ecadherin expression. Cell Cycle 2009;8:2064-9.
23. Yu J, Ohuchida K, Mizumoto K, Sato N, Kayashima T, Fujita H, et al. MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. Mol Cancer 2010;9:169.
24. Neves R, Scheel C, Weinhold S, Honisch E, Iwaniuk KM, Trompeter HI, et al. Role of DNA methylation in miR-200c/141 cluster silencing in invasive breast cancer cells. BMC Res Notes 2010;3:219.
25. Ding L, Xu Y, Zhang W, Deng Y, Si M, Du Y, et al. MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res 2010;20:784-93.
26. Tsukamoto Y, Nakada C, Noguchi T, Tanigawa M, Nguyen LT, Uchida T, et al. MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res 2010;70:2339-49.
27. Avissar M, Christensen BC, Kelsey KT, Marsit CJ. MicroRNA expression ratio is predictive of head and neck squamous cell carcinoma. Clin Cancer Res 2009;15:2850-5.
28. Mathé EA, Nguyen GH, Bowman ED, Zhao Y, Budhu A, Schetter AJ, et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res 2009;15:6192-200.
29. Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008;47:1955-63.
30. Zhang X, Yan Z, Zhang J, Gong L, Li W, Cui J, et al. Combination of hsa-miR-375 and hsa-miR-142-5p as a predictor for recurrence risk in gastric cancer patients following surgical resection. Ann Oncol 2011 Feb 22. [Epub ahead of print].
31. de Souza Rocha Simonini P, Breiling A, Gupta N, Malekpour M, Youns M, Omranipour R, et al. Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Res 2010;70:9175-84.
32. Hanke M, Hoefig K, Merz H, Feller AC, Kausch I, Jocham D, et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 2009;28:655-61.
33. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008;105:10513-8.
34. Tu LC, Yan X, Hood L, Lin B. Proteomics analysis of the interactome of N-myc downstream regulated gene 1 and its interactions with the androgen response program in prostate cancer cells. Mol Cell Proteomics 2007;6:575-88. (Pubitemid 46630091)
35. Melotte V, Qu X, Ongenaert M, van Criekinge W, de Bruïne AP, Baldwin HS, et al. The N-myc downstream regulated gene (NDRG) family: diverse functions, multiple applications. FASEB J 2010; 24:4153-66.
36. Hughes H, Stephens DJ. Assembly, organization, and function of the COPII coat. Histochem Cell Biol 2008;129:129-51.
37. Cho S, Ryoo J, Jun Y, Ahn K. Receptor-mediated ER export of human MHC class I molecules is regulated by the C-terminal single amino acid. Traffic 2011;12:42-55.
38. Blades RA, Keating PJ, McWilliam LJ, George NJ, Stern PL. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 1995;46:681-6; discussion 686-7.
39. Seliger B, Stoehr R, Handke D, Mueller A, Ferrone S, Wullich B, et al. Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. Cancer Immunol Immunother 2010;59:529-40.